Robotic Choledochal Cyst Excision With Intracorporeal Roux‐en‐Y Hepaticojejunostomy in Adolescent and Adult Patients: Clinical and Quality‐of‐Life Outcomes
Lokesh Agarwal, Ankit Rai, Vaibhav Kumar Varshney, Subhash Soni, B. Selvakumar, Peeyush Varshney, Ayushi Agarwal, Binit Sureka, Taruna YadavABSTRACT
Introduction
This study evaluates clinical and health‐related‐quality‐of‐life (HRQOL) outcomes following robotic choledochal cyst (CDC) excision with intracorporeal Roux‐en‐Y hepaticojejunostomy.
Method
Prospectively maintained data from 17 consecutive patients undergoing robotic CDC excision with the da Vinci Xi system (January 2017–October 2024) were retrospectively analysed.
Results
Fifteen patients were female; median age was 22 year. Cyst types included Ia(6), Ic(3), IVa(5), II(1), and VIb(2). Median operative time was 360 min, blood loss 50 mL, and hospital stay 4 days. Postoperative complications occurred in three patients, including one clinically‐relevant grade‐B postoperative‐pancreatic‐fistula requiring image‐guided drainage (Clavien–Dindo IIIa), one biochemical POPF, and one episode of mild acute‐pancreatitis. At a median follow‐up of 36.5‐month (IQR 35–43), no anastomotic strictures, malignancy, or biliary complications were noted. At 12‐month, the median Gastrointestinal‐Quality‐of‐Life‐Index (GIQLI) score was 135 (IQR 133.5–136).
Conclusion
Robotic CDC excision with intracorporeal reconstruction appears feasible and safe in selected patients, with favourable perioperative and functional outcomes.